Progressive Trabecular Osteopenia in Women With Hyperprolactinemic Amenorrhea

Baum, Howard B. A.; Rosenthal, Daniel I.; Saxe, Velia; Charpie, Peggy M.; Klibanski, Anne

doi:10.1097/00006254-199302000-00025

Cited by 22 publications

(45 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In agreement with the literature, including previous data on Brazilian patients, the present study shows that bone density is lower in women with prolactinoma than in healthy controls [1][2][3]5]. As mentioned before, this study differs from all the previous ones as it is based on more modern densitometric diagnostic criteria for premenopausal women.…”

Section: Discussionsupporting

confidence: 90%

“…Previous studies have shown that patients with prolactinoma are susceptible to developing osteopenia and osteoporosis [1][2][3][4][5][6]. The prolactinoma-related bone loss can be severe and affect young patients, since it can restrict peak bone mass acquisition [5].…”

Section: Introductionmentioning

confidence: 99%

“…The aims of this study were: (1) to evaluate bone density in women with prolactinoma and healthy controls, using dual energy x-ray absorptiometry (DXA), (2) to classify the results according to the current ISCD criteria, and (3) to correlate bone density with lean and fat masses, biochemical data, and clinical aspects of prolactinomas.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Bone density in women with prolactinoma treated with dopamine agonists

et al. 2007

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bone density in women with prolactinoma treated with dopamine agonists

et al. 2007

View full text Add to dashboard Cite

show abstract

“…The traditional paradigm is that gonadal dysfunction is the most important factor leading to bone loss in hyperprolactinemic patients, since low BMD was already reported specifically in amenorrheic women [5][6][7] and hypogonadal men [8,9]. However, there is also evidence that PRL may have sex hormones-independent effects on bone remodelling [11][12][13][14].…”

Section: Discussionmentioning

confidence: 99%

“…PRL-induced hypogonadism is also considered the main mechanism leading to decreased bone mineral density (BMD) in patients with hyperprolactinemia [5][6][7][8][9]. However, there is also evidence that PRL excess may directly influence bone remodelling and bone metabolism [10][11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas

et al. 2011

View full text Add to dashboard Cite

Hyperprolactinemia may cause bone loss but data on fractures are scanty. The aim of this study was to evaluate the prevalence of vertebral fractures in women with prolactin (PRL)-secreting adenoma. In this cross-sectional study, 78 women (median age 45.5 years, range: 20-81) with PRL-secreting pituitary adenoma (66 with microadenoma and 12 with macroadenoma) and 156 control subjects, with normal PRL values and with comparable age to patients with hyperprolactinemia, were evaluated for vertebral fractures by a morphometric approach and for bone mineral density (BMD) by a dual-energy X-ray absorptiometry at lumbar spine. Vertebral fractures were shown in 25 patients with PRL-secreting adenoma (32.6%) and in 20 controls (12.8%, P < 0.001). Fractured patients were significantly older (P < 0.001) and had lower BMD T-score (P < 0.001), longer duration of disease (P < 0.001), higher serum PRL (P = 0.004) and lower serum IGF-I (P < 0.001) values as compared to patients who did not fracture. The prevalence of vertebral fractures was significantly (P < 0.001) higher in post-menopausal women with PRL-secreting adenoma as compared to pre-menopausal patients. Fractures occurred more frequently (P = 0.01) in patients with untreated hyperprolactinemia versus patients treated with cabergoline. Logistic regression analysis demonstrated that duration of disease maintained a significant correlation with vertebral fractures (odds ratio 1.16, C.I. 95% 1.02-1.33) even after correction for age, menopausal status, treatment with cabergoline, BMD, serum IGF-I and serum PRL values. Hyperprolactinemia is associated with high prevalence of radiological vertebral fractures in women with PRL-secreting adenoma.

show abstract

Preclinical risk assessment of drug‐induced hypo‐ and hyperprolactinemia

Hargreaves

Harleman

2011

J of Applied Toxicology

View full text Add to dashboard Cite

Drug-induced changes in prolactin signaling may obscure interpretation of preclinical toxicological endpoints. However, with informed consideration, classic hallmarks of hypo-/hyperprolactinemia can be recognized in short- and long-term rodent bioassays. Findings can be supported and expanded with additional in vivo and in vitro datasets. When taken together with human epidemiological evidence pertaining to the consequences of drug-induced hypo-/hyperprolactinemia, such findings permit both an analysis of human relevance and an assessment of human risk.

show abstract

Progressive Trabecular Osteopenia in Women With Hyperprolactinemic Amenorrhea

Cited by 22 publications

References 0 publications

Bone density in women with prolactinoma treated with dopamine agonists

Bone density in women with prolactinoma treated with dopamine agonists

High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas

Preclinical risk assessment of drug‐induced hypo‐ and hyperprolactinemia

Contact Info

Product

Resources

About